Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Fig. 4

Treatment outcomes according to the cfDNA level and I-score. Comparison of (a) the cfDNA level and (b) the I-score between patients who achieved disease control and patients who did not. (c–h) Kaplan–Meier for (c) TTP and (d) OS according to high vs. low cfDNA level; and (e) TTP and (f) OS to high vs. low I-score; and (g) TTP and (h) OS according to I-score quartile. Abbreviations: cfDNA, cell-free DNA; TTP, time to progression; OS, overall survival; PD, progressive disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us